The VISCHER team, led by partner Robert Bernet (Corporate / M & A - pictured) includes Peter Kühn (Counsel, Corporate / M & A), Florian Kambor (Junior Associate, Corporate / M & A) and Christian Wyss (Partner, IP).
Tags :Christian Wyss
VISCHER is advising Noema Pharma in this transaction. The team is led by Matthias Staehelin (Corporate, pictured left). Walder Wyss advised Gilde Healthcare Partners, Polaris Partners, Invus Capital and BioMedInvest as investors. The team included
The team included Christian Wyss (Partner, Corporate / M&A - pictured), Luzius Zumstein (Senior Associate, Corporate / M&A) and Dario Glauser (Trainee, Corporate / M&A).
VISCHER advised Polyphor on all legal issues in connection with the transaction. The team was led by Christian Wyss (pictured) with Matthias Staehelin, Fiona Gao, Camill Oberhausser (all Corporate) and Nadia Tarolli (Tax).
VISCHER advises T3 Pharmaceuticals on all legal issues in connection with the transaction. The team consists of Christian Wyss (Partner, Corporate / M&A - pictured), Pauline Pfirter (Associate, Corporate / M&A), Ruben Masar (Associate, Corporate /
The team included partner Christian Wyss (Life Sciences - pictured), associate Timothy Woodtli (Corporate/M&A), associate Francesca Pesenti (Corporate/M&A), and associate Gian Geel (Employment).
FoRx Therapeutics, a Basel-based biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways activated in cancer, completes a EUR 10M seed-financing round
